Last reviewed · How we verify

NCT04217096

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Status unknown Phase 4 Last updated 3 January 2020
What this trial tests

Phase 4 trial testing Paclitaxel liposome in Advanced Pancreatic Cancer in 40 participants. Status unknown.

Timeline
1 January 2020
Primary endpoint
30 September 2022
31 March 2023

Quick facts

Lead sponsorFudan University
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 January 2020
Primary completion30 September 2022
Estimated completion31 March 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Advanced Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.
    Wang S, Zheng Y, Yang F, Zhu L, et al · · 2021 · cited 252× · PMID 34219130 · DOI 10.1038/s41392-021-00659-4
  2. Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities.
    Claridge B, Lozano J, Poh QH, Greening DW. · · 2021 · cited 132× · PMID 34616741 · DOI 10.3389/fcell.2021.734720
  3. Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.
    Chavda VP, Patel AB, Mistry KJ, Suthar SF, et al · · 2022 · cited 75× · PMID 35425710 · DOI 10.3389/fonc.2022.867655
  4. Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials.
    Taléns-Visconti R, Díez-Sales O, de Julián-Ortiz JV, Nácher A. · · 2022 · cited 61× · PMID 35457065 · DOI 10.3390/ijms23084249
  5. Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies.
    Wei QY, Xu YM, Lau ATY. · · 2020 · cited 60× · PMID 32998391 · DOI 10.3390/cancers12102783
  6. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.
    Zhang CY, Liu S, Yang M. · · 2022 · cited 28× · PMID 36632312 · DOI 10.3748/wjg.v28.i48.6827
  7. Theranostic nanoparticles for detection and treatment of pancreatic cancer.
    Agarwal H, Bynum RC, Saleh N, Harris D, et al · · 2024 · cited 6× · PMID 39140128 · DOI 10.1002/wnan.1983
  8. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
    Yang XY, Lu YF, Xu JX, Du YZ, et al · · 2023 · cited 6× · PMID 36771172 · DOI 10.3390/molecules28031506

Verify or expand the search:

Other trials of Paclitaxel liposome

Trials testing the same drug.

Other recruiting trials for Advanced Pancreatic Cancer

Currently open trials in the same condition.

Other Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04217096.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing